

Pfizer Research Grant Request for Proposals

Competitive Grant Program – Pfizer Internal Review Process

Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma

Overview

Relapsed and/or refractory multiple myeloma (RRMM) remains an area of high unmet need, characterized by cumulative treatment resistance, decreasing depth and durability of response across successive lines of therapy, and increasing complexity of treatment sequencing in routine clinical practice. While clinical trials demonstrate the efficacy of novel agents, real world evidence is critical to complement trial findings by capturing the effectiveness, safety, and feasibility of therapies in everyday care, including populations under represented in trials, such as older patients and those with comorbidities.

This competitive grant program supports independent real world research evaluating the safety, effectiveness, and implementation of elranatamab in RRMM, with a focus on treatment sequencing, real world utilization, and outcomes in heterogeneous patient populations, as well as care delivery models that address educational, organizational, and system level barriers, particularly in community practice settings, to inform evidence based clinical decision making.

Geographic Scope

China, France, Germany, Italy, Japan, Spain, Turkey and the United Kingdom.

Project Types and Area of Interest

Projects that will be considered for Pfizer support will focus on:

- *Safety and efficacy of Elranatamab in the context of real-world use*
- *Optimal treatment sequencing, including impact of prior treatments (BsAb, CAR-T, ADC) and washout periods on T cell fitness and Elranatamab outcomes*
- *Characterization and clinical management of long-term immunosuppression and infectious risk, including Ig replacement protocols*
- *Outpatient administration of Elranatamab in real world practice and CRS/ICANS mitigation strategies, including impact on quality of life and healthcare resource utilization*
- *Real-World implementation of Elranatamab delivery in community setting, with a focus on strategies that overcome operational barriers while maintaining patient safety, care quality, and equitable access*
- *Identifying clinical and biological features of refractoriness, early- or late-response, relapse to Elranatamab and establishing response biomarkers*

Key Milestones

Submission Deadline	Anticipated Grant Award Notification	Anticipated Project Start Date
12 JUN 2026	JUL 2026	NOV 2026

Funding Range and Project Length

Individual projects requesting up to $200,000 will be considered, although smaller requests (around $50,000) are also encouraged. Through this Request for Proposal, funding will be awarded to support up to ten selected studies whether national or multi-country.

I. Eligibility

Geographic Scope:

- China, France, Germany, Italy, Japan, Spain, Turkey and the United Kingdom.

Applicant Eligibility Criteria

- The institution and Principal Investigator (PI) must be based in one of the eligible countries noted above.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI's research coordinator).
- The PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer International LLC. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer International LLC may be subject to rescission.

II. Requirements

Primary Area of Interest:

- Oncology – Hematologic - RES

General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on:

- Safety and efficacy of Elranatamab in the context of real-world use
- Optimal treatment sequencing, including impact of prior treatments (BsAb, CAR-T, ADC) and washout periods on T cell fitness and Elranatamab outcomes
- Characterization and clinical management of long-term immunosuppression and infectious risk, including Ig replacement protocols
- Outpatient administration of Elranatamab in real world practice and CRS/ICANS mitigation strategies, including impact on quality of life and healthcare resource utilization
- Real-World implementation of Elranatamab delivery in community setting, with a focus on strategies that overcome operational barriers while maintaining patient safety, care quality, and equitable access
- Identifying clinical and biological features of refractoriness, early- or late-response, relapse to Elranatamab and establishing response biomarkers.
- **Important clarification**

  Outpatient administration within the scope of this RFP must remain strictly **label-consistent during step-up (priming) dosing**. For the purposes of this RFP, the term *"outpatient"* refers exclusively to **supervised hospital or ambulatory settings** (e.g., day clinic/day hospital) with **appropriately trained healthcare professionals** and **immediate access to escalation capabilities**. Home-based administration or administration in other non-medical facilities during the step-up phase is explicitly **out of scope**.

  This approach is aligned with the **EU Summary of Product Characteristics (SmPC)**, which states:

"Due to the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), patients should be monitored for signs and symptoms for 48 hours after administration of each of the two step-up doses and instructed to remain within proximity of a healthcare facility."

Given that **regulatory label requirements for step-up dosing vary across geographies**, proposals involving step-up dosing must be designed and conducted in full compliance with the **applicable local approved labels**, including **specific setting and monitoring requirements** and **mandatory hospitalization**, where required.

Expected Approximate Monetary Range of Grant Applications

IMPORTANT: Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver.

- Individual study grant requests up to $200,000 will be considered, although smaller requests (around $50,000) are also encouraged.
- If there is strong scientific justification and well-supported in the budget details, applicants may request up to a maximum of $250,000 per study.
- Through this Request for Proposal, funding will be awarded to support up to ten selected studies.
- Preference will be given to national and multi-country research projects supported by a robust and well-defined methodology and a clear plan for timely data generation. Proposals should be designed to deliver high-quality, clinically meaningful evidence with a feasible and well-defined timelines enabling timely execution and data generation.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:



IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

*Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5)

How to Submit:

IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to https://www.cybergrants.com/pfizer/Research and sign in.
  - Note: there are individual portals for each grant application type. Please be sure to use the URL above.
  - First-time users should click "Create your password".
- Click the "**Start A New Research Grant Application**" button.
- Requirements for submission:
  - Complete all required sections of the online application
  - **IMPORTANT:** Upload proposal (see Appendix) in the Proposal/Protocol field.
- In the application:
  - For the question "**Competitive Grant?**" select "**Yes**"
  - Select the following Primary Area of Interest: **Oncology – Hematologic - RES**
  - Select the following Competitive Grant Program Name: **2026 Onc Int Research Multiple Myeloma**

Questions:

- If you encounter any technical difficulties with the website, please click here or the "Technical Questions" link at the bottom of the page in cybergrants.
- Please click here to view "Frequently Asked Questions" regarding the Competitive Grant Program.
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Nicola Fenderico (Nicola.Fenderico@Pfizer.com), with the subject line "Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma May 2026".

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
- For selected projects: Pfizer will support only those projects for which an executed copy of the Agreement, the Protocol, and documentation of IRB/IEC approval, regulatory approval (if applicable), exemption, or waiver will be received by 15 November 2026.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.

About Pfizer Grants

Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Appendix

IMPORTANT: RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective.

Assessment of Need for the Project

- This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question.

Target Audience

- Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population.
- Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan.

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures.
- Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.
- An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
- Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.

Organization Detail

- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.

Budget Detail

- While estimating your budget please keep the following items in mind:
- General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
- The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
- Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
- It should be noted that grants awarded through GMGP cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please click here for details.

Required Documents

- Project Plan or Proposal
- Initial Study Protocol